← FDA DRUG APPROVALS

FDA ANDA · ANDA215834

MIDOSTAURIN

Sponsor: LOTUS PHARM CO LTD

APPLICATION
ANDA215834
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
None (Tentative Approval)

Products

MIDOSTAURINNone (Tentative Approval)
MIDOSTAURIN 25MG · CAPSULE · ORAL

Approval history

2022-08-24UNKNOWN · Original · standardLetterTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →